India Regulator Also Probes Ranbaxy Plants For Drug Safety
This article was originally published in PharmAsia News
The Drugs Controller General of India has inspected all Ranbaxy Laboratories facilities in the country and collected samples to be tested for safety and efficacy over the next month.
You may also be interested in...
The efforts to upgrade FDA’s information technology infrastructure may be opening up into an opportunity to reinvent its processes for regulatory decision making.
FDA should have all coronavirus vaccines evaluated by Vaccines and Related Biological Products Advisory Committee before approval, Democratic senators and representatives say; House subcommittee also wants FDA to require 30,000 participants in Phase III trials.
Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.